Cover Image
市場調查報告書

脈絡膜新生血管:開發中產品分析

Choroidal Neovascularization - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213111
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
脈絡膜新生血管:開發中產品分析 Choroidal Neovascularization - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 51 Pages
簡介

所謂脈絡膜新生血管薄膜(NCVM)是指網膜下方(脈絡膜)血管增生,造成視力低落。主要症狀有無伴隨疼痛的喪失視力,及視力改變,色覺異常等。主要的治療方法有抗VEGF(血管內皮層生長因子)抗體和雷射手術,光力學療法等。

本報告提供全球各國治療脈絡膜新生血管所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

脈絡膜新生血管概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

脈絡膜新生血管:企業開發中的治療藥

脈絡膜新生血管:大學/機關研究中的治療藥

脈絡膜新生血管:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

脈絡膜新生血管:企業開發中的產品

脈絡膜新生血管:大學/機關研究中的產品

脈絡膜新生血管的治療藥的開發企業

  • Affitech A/S
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Iconic Therapeutics, Inc.
  • Mabion SA
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Promedior, Inc.
  • 三和化學研究所

脈絡膜新生血管:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

脈絡膜新生血管:最近的開發平台趨勢

脈絡膜新生血管:暫停中的計劃

脈絡膜新生血管:中止開發的產品

脈絡膜新生血管:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9750IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2017, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Choroidal Neovascularization - Overview
    • Choroidal Neovascularization - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Choroidal Neovascularization - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Choroidal Neovascularization - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd
    • Formycon AG
    • Graybug Vision Inc
    • Isarna Therapeutics GmbH
    • Lupin Ltd
    • Mabion SA
    • NovelMed Therapeutics Inc
    • Noxxon Pharma AG
    • Promedior Inc
  • Choroidal Neovascularization - Drug Profiles
    • ACX-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ayuv-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-0036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegylated doxorubicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7716 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Choroidal Neovascularization - Dormant Projects
  • Choroidal Neovascularization - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Choroidal Neovascularization, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Choroidal Neovascularization - Pipeline by Formycon AG, H2 2017
  • Choroidal Neovascularization - Pipeline by Graybug Vision Inc, H2 2017
  • Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H2 2017
  • Choroidal Neovascularization - Pipeline by Lupin Ltd, H2 2017
  • Choroidal Neovascularization - Pipeline by Mabion SA, H2 2017
  • Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H2 2017
  • Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2017
  • Choroidal Neovascularization - Pipeline by Promedior Inc, H2 2017
  • Choroidal Neovascularization - Dormant Projects, H2 2017
  • Choroidal Neovascularization - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Choroidal Neovascularization - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Choroidal Neovascularization, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top